AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study NCT01950104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 embryo biopsy
Description: Embryo biopsy is applied at day 3 of the embryo development.
Study NCT01950104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blastocyst biopsy
Description: Embryo biopsy is applied at the blastocyst stage of the embryo development
Study NCT00992628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh (direct vision) laryngoscope
Description: Macintosh (direct vision) laryngoscope
Study NCT00992628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope videolaryngoscope (indirect vision)
Description: GlideScope videolaryngoscope (indirect vision)
Study NCT04514640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Calm app
Description: All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention.
Study NCT00510016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine HCL
Description: Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
Study NCT03326817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients receive standard care
Study NCT03326817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Robotic Glove Group
Description: This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
Study NCT01844115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01844115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Viibryd
Study NCT02300285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
Study NCT00451555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
Study NCT00451555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fulvestrant
Description: 500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
Study NCT02300285 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
Study NCT01070823 — intervention group
Intervention type: DRUG
Intervention: Tysabri® (natalizumab)
Description: Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
Study NCT02084719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oraquick HCV Rapid Antibody Test
Study NCT02084719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard algorithm
Study NCT02084719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard algorithm
Study NCT03305224 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ra-223 in combination with enzalutamide
Description: Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
Study NCT01197820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96\*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128\*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed
Study NCT01380990 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous EFS-ADA LV CD34+ cells
Description: Autologous EFS-ADA LV CD34+ cells (OTL-101\*) are infused intravenously
Study NCT01380990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Haematopoietic Stem Cell Transplantation (HSCT)
Description: Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
Study NCT01380990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is used for non-myeloablative conditioning
Study NCT01380990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Ada
Description: Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
Study NCT01229982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Punctal Plug
Study NCT04848181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyproterone acetate
Description: two weeks Cyproterone acetate administration before TURP
Study NCT04848181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: finasteride
Description: two weeks finasteride administration before TURP
Study NCT04848181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no treatment received
Description: no treatment received before TURP
Study NCT01836627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsufflation therapy
Description: 15 minutes twice a day of hyperinsufflation with Cough Assist® device
Study NCT04111523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)
Study NCT01305278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Nintendo Wii Balance Gaming system
Description: Use of Nintendo Wii Balance Gaming system
Study NCT02507882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL28B Polymorphism
Description: SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
Study NCT05523232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration training with 42 Hz
Description: Vibration exposure was given using a handheld vibration device.
Study NCT05523232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibration training with 63 Hz
Description: Vibration exposure was given using a handheld vibration device.
Study NCT02018172 — intervention group
Intervention type: DRUG
Intervention: somatropin
Study NCT01684982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus eluting stent
Description: experimental arm of a comparison between drug eluting stents
Study NCT01684982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus eluting stent
Description: control arm of a comparison between drug eluting stents
Study NCT01120080 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Practical Counseling
Description: To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
Study NCT02507882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miRNA quantification
Description: RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen).
Study NCT02796963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention
Description: The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
Study NCT02796963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional intervention campaign
Description: The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
Study NCT03580616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Serine
Description: L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
Study NCT05088837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.
Study NCT05088837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice and heat packs
Description: Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
Study NCT04186403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.
Study NCT03501043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport
Description: Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
Study NCT00852670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Description: ACT-128800 administered orally once daily
Study NCT00852670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered orally once daily
Study NCT04632732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab
Study NCT04632732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.
Study NCT02384655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenugreek seed meal
Description: 3x3 capsules of fenugreek seeds per day for 14 days
Study NCT01263106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 18-mg LY2216684 oral dose
Study NCT01263106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: 200-mg theophylline oral dose
Study NCT03662360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils
Description: Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
Study NCT02009696 — intervention group
Intervention type: DEVICE
Intervention: Patients with a ProMRI Pacemaker System
Description: Bradycardia Slow Heart Beat
Study NCT02009696 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: MRI scan of heart/chest or thoracic spine.
Study NCT03936140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
Study NCT03936140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
Study NCT01364974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT01364974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT01364974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01642069 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03479190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided injection of Platelet rich plasma
Description: Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
Study NCT03479190 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guided injection of Normal Saline
Description: ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
Study NCT01354275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle
Description: 150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
Study NCT01354275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GnRH Antagonist
Description: GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
Study NCT02069769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication with oncology team
Description: Oncology team will contact patients and families via telephone at specific intervals
Study NCT01569035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: 3 mg warfarin oral tablet for 2 to 3 weeks
Study NCT00798356 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yoga training
Description: Yoga training for 12 weeks
Study NCT00025584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00025584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03584776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
Study NCT00630214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral calcium plus vitamin D
Description: calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
Study NCT00630214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral calcium alone
Description: calcium carbonate (3 g/day, 1 g every 8 h)
Study NCT03176589 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: positive expiratory pressure (PEP)
Description: Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
Study NCT03176589 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo comparator, Deep inspiration and expression in a placebo tube without resistance
Description: Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
Study NCT03176589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing maneuvers
Description: deep breathing maneuvers 3 times 10 breahs without any device at expiration
Study NCT03547284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugarless gum
Description: 81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours